ImageneBio Inc

NASDAQ:IMA

Biotechnology

Healthcare
$4.61 +6.06%

+$0.35 today

Market cap
$52.00M
Beta
0.72
P/E (TTM)
-1.5
EPS (TTM)
-$4.02
52W Low $3.94High $18.00

Volume 0.00M

Average 0.35M

IMA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

ImageneBio IncNASDAQ: IMA

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $174K fell 95.3% year over year, in line with the -95.0% change in trailing-twelve-month cost of revenue. Sequentially, it fell 69.0% from the prior quarter. Over 3 fiscal years it compounded at -74.8% a year.

Context

  • Cost of revenue amounted to 129.1% of revenue in FY2025, up 85.5 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -95.3% toward the trailing-twelve-month pace of -95.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$174K-69.0% QoQ
Last fiscal yearDec 2025
$1.03M-32.3% YoY
LTMMar 2026
$780K-95.0% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-95.3%——
1 year-32.3%——
3-year CAGR-74.8%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
1.03M USD
Year-over-year change
-32.3%
4-year CAGR
-61.5%

Cost of Revenue vs competitors

How IMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -95.0% is the lowest of 4, against a peer median of -28.6%.
  • Over three fiscal years its annual growth of -74.8% compares with a peer median of -4.0%.
IMA Competitors
Cost of Revenue for IMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IFRXInflaRx N.V.LTM Mar 2026€7.26M EUR+133.7%—24746.3%
STTKShattuck Labs, Inc.LTM Mar 2026$1.82M USD-36.2%—182.0%
STROSutro Biopharma, Inc.LTM Mar 2026$1.28M USD-28.6%-4.0%1.3%
IMAImageneBio IncLTM Mar 2026$780K USD-95.0%-74.8%—
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$666K USD———
CNTXContext Therapeutics Inc.LTM Mar 2026$40.17K USD———
OVIDOvid Therapeutics Inc.LTM Mar 2026$35K USD——0.5%
KLRSKalaris Therapeutics IncLTM Mar 2026$20K USD———
CNTBConnect Biopharma Holdings LimitedFY2025$0 USD——0.0%
Peer median (excluding IMA) —-28.6%-4.0%1.3%

Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.99M15.62M9.16M3.5M800K
Cost of Revenue47.11M64.32M1.02M1.53M1.03M
Gross Profit(16.12M)(48.7M)8.14M3.5M(233K)
Gross Margin-52.0%-311.8%88.9%100.0%-29.1%
Research & Development47.11M64.32M59.65M32.11M28.53M
Selling, General & Admin18.02M22.2M24.93M8.39M20.73M
Operating Expenses18.02M22.2M83.56M40.5M48.22M
Depreciation & Amortization544K751K1.02M1.53M1.03M
EBITDA(33.57M)(68.01M)(67.31M)(35.03M)(44.67M)
EBITDA Margin-108.3%-435.5%-734.8%-1000.8%-5583.3%
Operating Income(34.14M)(70.9M)(75.42M)(37M)(48.45M)
Operating Margin-110.2%-454.0%-823.3%-1057.1%-6056.4%
Interest Income23K2.15M7.11M7.37M2.04M
Interest Expense00000
Other Income / Expenses23K2.14M7.09M445K2.75M
Income Before Tax(34.12M)(68.77M)(68.33M)(36.56M)(45.7M)
Pre-Tax Margin-110.1%-440.3%-745.9%-1044.4%-5712.4%
Income Tax Expense00(162K)13K(350K)
Net Income(34.12M)(68.77M)(68.17M)(36.57M)(45.35M)
Net Margin-110.1%-440.3%-744.2%-1044.8%-5668.6%
EPS (Basic)(0.95)(1.90)(1.63)(1.02)(10.76)
EPS (Diluted)(0.95)(1.90)(1.63)(1.02)(10.76)
Weighted Avg Shares35.98M36.19M41.74M48.26M4.87M
Weighted Avg Shares (Diluted)35.98M36.19M41.74M48.26M4.87M

ImageneBio Inc

NASDAQ:IMA

Intrinsic Alpha fair value

Locked

Current Price

$4.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.